Skip to main content
Erschienen in: Endocrine 1/2018

02.06.2017 | Letter to the Editor

Bone mineral density in older patients with never-treated congenital hypogonadotropic hypogonadism

verfasst von: Luigi Maione, Annamaria Colao, Jacques Young

Erschienen in: Endocrine | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Excerpt

Sex steroids are major regulators of skeletal development and bone mineral content, and sex steroid deficiency can thus lead to osteoporosis and fractures in later life [1]. Hypogonadism in both genders is associated with bone loss and frailty. Its deleterious effects on bone mineral density (BMD) are epitomized by women with ovarian failure and by aging men undergoing surgical or pharmacological castration for prostate cancer [1]. …
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat J.P. Bonjour, T. Chevalley, Pubertal timing, bone acquisition, and risk of fracture throughout life. Endocr. Rev. 35, 820–847 (2014)CrossRefPubMed J.P. Bonjour, T. Chevalley, Pubertal timing, bone acquisition, and risk of fracture throughout life. Endocr. Rev. 35, 820–847 (2014)CrossRefPubMed
2.
Zurück zum Zitat U. Boehm, P.M. Bouloux, M.T. Dattani, N. de Roux, C. Dodé, L. Dunkel, A.A. Dwyer, P. Giacobini, J.P. Hardelin, A. Juul, M. Maghnie, N. Pitteloud, V. Prevot, T. Raivio, M. Tena-Sempere, R. Quinton, J. Young, Expert consensus document: European Consensus Statement on congenital hypogonadotropic hypogonadism-pathogenesis, diagnosis and treatment. Nat. Rev. Endocrinol. 11, 547–564 (2015)CrossRefPubMed U. Boehm, P.M. Bouloux, M.T. Dattani, N. de Roux, C. Dodé, L. Dunkel, A.A. Dwyer, P. Giacobini, J.P. Hardelin, A. Juul, M. Maghnie, N. Pitteloud, V. Prevot, T. Raivio, M. Tena-Sempere, R. Quinton, J. Young, Expert consensus document: European Consensus Statement on congenital hypogonadotropic hypogonadism-pathogenesis, diagnosis and treatment. Nat. Rev. Endocrinol. 11, 547–564 (2015)CrossRefPubMed
3.
Zurück zum Zitat A.A. Dwyer, J. Tiemensma, R. Quinton, N. Pitteloud, D. Morin, Adherence to treatment in men with hypogonadotropic hypogonadism. Clin. Endocrinol. (2016). doi:10.1111/cen.13236 A.A. Dwyer, J. Tiemensma, R. Quinton, N. Pitteloud, D. Morin, Adherence to treatment in men with hypogonadotropic hypogonadism. Clin. Endocrinol. (2016). doi:10.​1111/​cen.​13236
4.
Zurück zum Zitat J. Iqbal, H.C. Blair, A. Zallone, L. Sun, M. Zaidi, Further evidence that FSH causes bone loss independently of low estrogen. Endocrine 41, 171–175 (2012)CrossRefPubMed J. Iqbal, H.C. Blair, A. Zallone, L. Sun, M. Zaidi, Further evidence that FSH causes bone loss independently of low estrogen. Endocrine 41, 171–175 (2012)CrossRefPubMed
5.
Zurück zum Zitat A. Garcia-Martin, R. Reyes-Garcia, J.M. Garcia-Castro, P. Rozas-Moreno, F. Escobar-Jimenez, M. Munoz-Torres, Role of serum FSH measurement on bone resorption in postmenopausal women. Endocrine 41, 302–308 (2012)CrossRefPubMed A. Garcia-Martin, R. Reyes-Garcia, J.M. Garcia-Castro, P. Rozas-Moreno, F. Escobar-Jimenez, M. Munoz-Torres, Role of serum FSH measurement on bone resorption in postmenopausal women. Endocrine 41, 302–308 (2012)CrossRefPubMed
Metadaten
Titel
Bone mineral density in older patients with never-treated congenital hypogonadotropic hypogonadism
verfasst von
Luigi Maione
Annamaria Colao
Jacques Young
Publikationsdatum
02.06.2017
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 1/2018
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-017-1334-1

Weitere Artikel der Ausgabe 1/2018

Endocrine 1/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.